Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma.
Weekly administration of the combination will prove to be feasible and tolerable at an
appropriate dose.